Last updated on November 2019

Spinraza in Adult Spinal Muscular Atrophy

Brief description of study

This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA (nusinersen) for up to 30 months.

Detailed Study Description

This is a prospective, longitudinal, multi-center, observational study designed to evaluate the safety, tolerability, and effectiveness of SPINRAZA (nusinersen) in ambulatory and non-ambulatory adult patients with SMA. Subjects with SMA II/III that are 18 years to 70 years of age who are planning to initiate treatment with SPINRAZA (nusinersen) as part of their clinical care plan will be enrolled in this study. This study does not provide SPINRAZA (nusinersen) or cover costs associated with standard clinical care.These patients will be treated by their respective physicians according to standard clinical practice. Study visits including standardized assessments of strength and function will occur at baseline, day 15 after treatment initiation, day 30, day 70, and then 4-month intervals through month 30.

Clinical Study Identifier: NCT03709784

Find a site near you

Start Over